Form 4 for TSHA Taysha Gene Therapies, Inc.
Accepted 2023-06-02 00:00:00 ET · period of report 2023-05-31 · accession 0001209191-23-033681 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-06-02 | 2023-05-31 | TSHA | Alam Kamran | CFO | A - Grant | — | +6,230 | 291.0K | +2% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-05-31 | A | A | 6,230 | — | 291,042 | D | — | — | (F1) Represents a performance restricted stock unit ("PRSU") award. The PRSUs were awarded on February 2, 2023 by the Compensation Committee (the "Compensation Committee") of the Issuer's Board of Directors as annual incentive compensation for 2022 performance. On May 31, 2023, the Compensation Committee certified the achievement of a certain performance goal. The PRSUs covered by this report vested upon certification. (F2) Each PRSU represented a contingent right to receive one share the Issuer's common stock. |